Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
About this item
Full title
Author / Creator
Drilon, Alexander , Clark, Jeffrey W. , Weiss, Jared , Ou, Sai-Hong Ignatius , Camidge, D. Ross , Solomon, Benjamin J. , Otterson, Gregory A. , Villaruz, Liza C. , Riely, Gregory J. , Heist, Rebecca S. , Awad, Mark M. , Shapiro, Geoffrey I. , Satouchi, Miyako , Hida, Toyoaki , Hayashi, Hidetoshi , Murphy, Danielle A. , Wang, Sherry C. , Li, Sherry , Usari, Tiziana , Wilner, Keith D. and Paik, Paul K.
Publisher
New York: Nature Publishing Group US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Nature Publishing Group US
Subjects
More information
Scope and Contents
Contents
MET
exon 14 alterations are oncogenic drivers of non-small-cell lung cancers (NSCLCs)
1
. These alterations are associated with increased MET activity and preclinical sensitivity to MET inhibition
2
. Crizotinib is a multikinase inhibitor with potent activity against MET
3
. The antitumor activity and safety of crizotinib were...
Alternative Titles
Full title
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Authors, Artists and Contributors
Author / Creator
Clark, Jeffrey W.
Weiss, Jared
Ou, Sai-Hong Ignatius
Camidge, D. Ross
Solomon, Benjamin J.
Otterson, Gregory A.
Villaruz, Liza C.
Riely, Gregory J.
Heist, Rebecca S.
Awad, Mark M.
Shapiro, Geoffrey I.
Satouchi, Miyako
Hida, Toyoaki
Hayashi, Hidetoshi
Murphy, Danielle A.
Wang, Sherry C.
Li, Sherry
Usari, Tiziana
Wilner, Keith D.
Paik, Paul K.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8500676
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8500676
Other Identifiers
ISSN
1078-8956
E-ISSN
1546-170X
DOI
10.1038/s41591-019-0716-8
